A Study to Evaluate the Pharmacokinetics and Safety of Levofloxacin in Patients With Varying Degrees of Renal Function.
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Renal Diseases
Intervention: Levofloxacin (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The primary objective was to evaluate the pharmacokinetics and safety of two dosing regimens
of levofloxacin in patients with varying degrees of renal function.
Clinical Details
Official title: An Open-Label Randomized Multiple-Dose Study to Evaluate Levofloxacin Steady-State Pharmacokinetics and Safety in Subjects With Varying Degrees of Renal Function
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Evaluation of the pharmacokinetics of two dosing regimens of levofloxacin in renally impaired and dialysis patients.
Secondary outcome: Safety of two dosing regimens of levofloxacin in renally impaired and dialysis patients.
Detailed description:
In this multiple-dose study conducted at 4 centers, the pharmacokinetics of two dosing
regimens of levofloxacin were assessed in medically stable men and women with varying degree
of renal function. The study consisted of a 21 day pretreatment screening phase, a 7-day
open label treatment phase, and a 7 day posttreatment phase (or a follow-up phase for
subjects with early study withdrawal). Patients were randomized into 1 of 10 treatment
groups, for a total of 6 patients per group, based on degree of renal function to ensure
that creatinine clearance values within each group represented the full range of values
defined in the Food and Drug Administration's (FDA) 1998 guideline for pharmacokinetic
studies in patients with impaired renal function. Fifty-nine patients were enrolled in the
study. All patients received a single 750-mg dose of levofloxacin on Day 1; subsequent doses
of either 250, 500, or 750 mg of levofloxacin (q24h or q48h) were based on renal function.
Blood samples were collected from each patient from Day 1 to Day 14 for pharmacokinetic
evaluation. Urine was collected on Days 1 and 7 before dosing and over specific time
intervals up to 24 or 48 hours postdosing depending on the patient's dosing regimen.
Dialysate samples were collected on Day 7 from HD patients immediately before dosing (as
dialysis began) and at the end of the dialysis treatment. Patients were confined overnight
at the study unit on Days 0, 1, 6, and 7, and remained confined until the 24 hour blood
samples were collected on Days 2 and 8. Safety was based on the incidence, relationship to
therapy, and severity of treatment-emergent adverse events and on changes in clinical
laboratory values (hematology, chemistry, and urinalysis), vital sign measurements,
electrocardiograms (ECGs), and physical examination findings. Single 750-mg dose of
levofloxacin on Day 1; subsequent doses of Levofloxacin 250 milligram (mg), 500 mg, and 750
mg tablets administered every 24 hours for 7 days or every 48 hours for 7 days
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- BMI between 18 and 35 kg/m2
- No prescription or over-the-counter medications for previous 7 days
- Negative tests for drug and alcohol abuse, HIV, hepatitis B and hepatitis C
- Medically stable based on medical history, physical examination, 12-lead
electrocardiograms, toxicology, antigen, and antibody screens, and clinical
laboratory evaluations
- Stable renal function based on calculated creatine clearance for non-dialysis
patients and the same dialysis treatment for at least 6 months prior to screening for
dialysis patients
- Patients with creatinine clearance =80 mL/min who require treatment for renal
impairment or other chronic disease (e. g., well-controlled diabetes, hypertension)
must be on a stable treatment plan (medicines, doses, and regimens) for at least 2
months prior to Day 1 and during the entire study
- Hematocrit (hct) within the normal range based on patients' renal function at
screening
Exclusion Criteria:
- Allergic reaction to quinolones
- Known or suspected allergy to heparin
- Clinically significant ECG or clinical laboratory abnormalities
- Creatinine clearance <80 mL/min whose medical condition was unstable
- creatinine clearance >= 80 mL/min who required concomitant medication during the
study
- Poorly controlled type 1 or type 2 diabetes
- Patients with creatinine clearance >= 50 mL/min with screening blood pressure outside
the normal range (sitting systolic blood pressure <90 or >140 mm mercury [Hg] or
diastolic blood pressure <60 or >90 mm Hg)
- Patients with CLCR <50 mL/min who had sitting systolic blood pressure <90 or >160 mm
Hg, or diastolic blood pressure <60 or >90 mm Hg
- Required warfarin treatment
- Required immunosuppressive medications for treatment of immune-mediated renal disease
or kidney transplant
- Pregnant or breastfeeding.
Locations and Contacts
Additional Information
An Open-Label Randomized Multiple-Dose Study to Evaluate Levofloxacin Steady-State Pharmacokinetics and Safety in Subjects With Varying Degrees of Renal Function
Starting date: October 2004
Last updated: June 6, 2011
|